.

Pharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Telaprevir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for telaprevir?

Telaprevir is the generic ingredient in one branded drug marketed by Vertex Pharms and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Telaprevir has one hundred and eighteen patent family members in thirty-six countries.

There are three drug master file entries for telaprevir.

Summary for Generic Name: telaprevir

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list3
Bulk Api Vendors: see list40
Clinical Trials: see list51
Patent Applications: see list154
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:telaprevir at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vertex Pharms
INCIVEK
telaprevir
TABLET;ORAL201917-001May 23, 2011DISCNNoNo8,529,882► Subscribe ► Subscribe
Vertex Pharms
INCIVEK
telaprevir
TABLET;ORAL201917-001May 23, 2011DISCNNoNo8,431,615► Subscribe ► Subscribe
Vertex Pharms
INCIVEK
telaprevir
TABLET;ORAL201917-001May 23, 2011DISCNNoNo7,820,671► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: telaprevir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,252,923Peptidomimetic protease inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: telaprevir

Country Document Number Estimated Expiration
European Patent Office2500021► Subscribe
Canada2585647► Subscribe
Japan2013060474► Subscribe
Taiwan201022242► Subscribe
Japan2012197289► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TELAPREVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0Finland► Subscribe
2012003,C1320540Lithuania► SubscribePRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
960Luxembourg► Subscribe91960, EXPIRES: 20260831
C0018France► SubscribePRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
2012 00007Denmark► SubscribePRODUCT NAME: TELAPREVIR OG FARMACEUTISK ACCEPTABLE SALTE OG/ELLER SOLVATER AF TELAPREVIR ELLER SOLVATER AF SADANNE SALTE; REG. NO/DATE: EU/1/11/720/001 20110919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc